Primary Record
trans-Dinoprostone
- In stock
- 5,573 g
- Purity
- 98.2 %
- CAS
- 36150-00-2
Compound Identifiers & Properties
- CAS
- 36150-00-2
- PubChem CID
- 5283116
- SMILES
- CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1C/C=C/CCCC(=O)O)O)O
- Canonical SMILES
- CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1C/C=C/CCCC(=O)O
Names & Synonyms
- trans-Dinoprostone
- 5-trans Prostaglandin E2
- 5-trans-Prostaglandin E2
- 5-trans-PGE2
- Lipoalprostadil
- 5,6-trans-PGE2
- 5,6-trans-Dinoprostone
- Prostaglandin E2
- 36150-00-2
- Alprostadil impurity H
- 8-isoprostaglandin E2
- Dinoprostone impurity C
- Alprostadil impurity H [EP]
- 5,6-trans PGE2
- UNII-6V30L285LP
- PGE2, 5,6-trans
- RefChem:103458
- Prostaglandin Impurity 12
- (5E)-prostaglandin E2)
- Alprostadil EP Impurity H
- AC1NR1K1
- Dinoprostone impurity C CRS
- 6V30L285LP
- (5E)-PROSTAGLANDIN E2
- 5-TRANSPROSTAGLANDINE2
- DTXSID40189722
- Dinoprostone Related Compound C
- orb1737643
- C20H32O5
- SCHEMBL23352614
- (5E)-PGE2
- Dinoprostone specified impurity C
- Dinoprostone specified impurity C [EP]
- DTXCID00112213
- XEYBRNLFEZDVAW-BRNHSORCSA-N
- HMS3648F17
- LBA15000
- 1463AH
- BDBM50213982
- LMFA03010148
- MFCD00135213
- PDSP2_001531
- ZINC12503216
- CID5283116
- ALPROSTADIL IMPURITY H [EP IMPURITY]
- Dinoprostone EP Impurity C (Free Base)
- DINOPROSTONE IMPURITY C [EP IMPURITY]
- J17.783K
- PD021141
- 9-oxo-11R,15S-dihydroxy-5E,13E-prostadienoic acid
- DINOPROSTONE RELATED COMPOUND C [USP-RS]
- HY-135023
- ALPROSTADIL IMPURITY H (EP IMPURITY)
- CS-0109078
- DINOPROSTONE IMPURITY C (EP IMPURITY)
- G91241
- Dinoprostone impurity, 5,6-trans-dinoprostone- [USP]
- DINOPROSTONE RELATED COMPOUND C (USP-RS)
- SR-01000946421
- (E)-7-((1R,2R,3R)-3-Hydroxy-2-((E)-(3S)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl)hept-5-enoic acid
- Prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-9-oxo-, (5E,11alpha,13E,15S)-
- SR-01000946421-1
- Dinoprostone impurity, 5,6-trans-dinoprostone-(USP)
- Dinoprostone impurity, 5,6-trans-dinoprostone-[USP]
- Q27265557
- (5Z,11alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid
- (E)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid
- 9-Oxo-11alpha,15S-dihydroxy-prosta-5E,13E-dien-1-oic acid
- (5E,11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid
- (5E,11R,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid
- (5E,13E,15S)-11alpha,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid
- (5E,13E,15S)-11alpha,15-Dihydroxy-9-oxoprosta-5,13-diene-1-oic acid
- 363-24-6
- (5E,11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-diene-1-oic acid
- 7-[(1R,2R,3R)-3-hydroxy-2-[(3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]-5-heptenoic acid
- PROSTA-5,13-DIEN-1-OIC ACID, 11,15-DIHYDROXY-9-OXO-, (5E,11.ALPHA.,13E,15S)-
- (5E)-7-((1R,2R,3R)-3-HYDROXY-2-((1E,3S)-3-HYDROXYOCT-1-ENYL)-5-OXOCYCLOPENTYL)HEPT-5-ENOIC ACID ((5E)-PROSTAGLANDIN E2)
- (5E)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoic acid
- (E)-7-((1R,2R,3R)-3-Hydroxy-2-((S,E)-3-hydroxyoct-1-en-1-yl)-5-oxocyclopentyl)hept-5-enoic acid
- (E)-7-((1R,2R,3R)-3-hydroxy-2-((S,E)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl)hept-5-enoic acid
- (E)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxo-cyclopentyl]hept-5-enoic acid
- (E)-7-{(1R,2R,3R)-3-Hydroxy-2-[(S,E)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl}hept-5-enoic acid; (E)-7-[(1R,2R,3R)-3-hydroxy-2-[(E)-(3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid; 5-trans-PGE2; (5E)-PGE2; Prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-9-oxo-, (5E,11alpha,13E,15S)-; (5E,11a,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; 5,6-trans-PGE2; 5-trans-PGE2; 5-trans-Prostaglandin E2; trans-Dinoprostone; Dinoprostone EP impurity C
- (Z)-7-[(1r,2r,3r)-3-Hydroxy-2-[(E,3s)-3-Hydroxyoct-1-Enyl]-5-Oxo-Cyclopentyl]hept-5-Enoic Acid
- P2E